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Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are
required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and
induce apoptosis of cancer cell lines in vitro and can also inhibit growth of pancreatic cancer xenografts in vivo. Thirty-six
patients with advanced pancreatic cancer received once daily oral treatment with seocalcitol with dose escalation every 2
weeks until hypercalcaemia occurred, following which patients continued with maintenance therapy. The most frequent
toxicity was the anticipated dose-dependent hypercalcaemia, with most patients tolerating a dose of 10–15 mg per day in
chronic administration. Fourteen patients completed at least 8 weeks of treatment and were evaluable for efﬁcacy, whereas 22
patients were withdrawn prior to completing 8 weeks’ treatment and in 20 of these patients withdrawal was due to clinical
deterioration as a result of disease progression. No objective responses were observed, with ﬁve of 14 patients having stable
disease in whom the duration of stable disease was 82–532 days (median=168 days). The time to treatment failure (n=36)
ranged from 22 to 847 days, and with a median survival of approximately 100 days. Seocalcitol is well tolerated in pancreatic
cancer but has no objective anti-tumour activity in advanced disease. Further studies are necessary to determine if this agent
has any cytostatic activity in this malignancy in minimal disease states.
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Carcinoma of the exocrine pancreas is the ﬁfth commonest cancer
and the fourth commonest cause of cancer deaths in the UK
(Williamson, 1988). Conventional methods of treatment including
surgery, radiotherapy and chemotherapy offer little hope of cure,
and the 5-year survival is reported as less than 1% with a median
survival of less than 3 months (Cancer of the Pancreas Task Force
Group, 1981).
Cancer of the pancreas responds poorly to most single-agent or
combination chemotherapy regimens. Nevertheless, palliative
chemotherapy can improve overall survival compared with no
treatment without impairing quality of life (Mallinson et al,
1980; Leonard et al, 1992; Palmer et al, 1994). Objective response
rates remain low with most single-agent chemotherapy including
21–26% with 5FU (Carter, 1975; Moertel, 1976), 26% with ifosfa-
mide (Bernard et al, 1986), 22% with epirubicin (Wils et al, 1985)
and 21% with cisplatin (Wils et al, 1993). Furthermore, the results
of combination chemotherapy have also been disappointing with
objective response rates of only 26% using 5FU with BCNU
(Kovach et al, 1974), 10% with 5FU and mitomycin C (Buroker
et al, 1979), 14% with FAM (5FU, doxorubicin, mitomycin C)
(Oster et al, 1986), and 17% with continuous infusional 5FU
administered with epirubucin and cisplatin (Evans et al, 1996).
More recently, gemcitabine was observed to have promising activity
in phase II trials (Casper et al, 1994; Rothenberg et al, 1996).
Gemcitabine has been shown to be more effective than 5FU in a
randomised, controlled phase III trial, although the 5FU was
administered in a sub-optimal way (Burris et al, 1997). However
the reported objective response rate for gemcitabine was only
5.4%, with only a modest survival advantage. Consequently, the
development of novel therapies in pancreatic cancer is justiﬁed.
The active vitamin D metabolite, 1,25-dihydroxyvitamin D3,
plays an important role in calcium homeostasis. In addition, it
has a role in the control of cellular differentiation and proliferation
(Bell, 1985; Reichel et al, 1989) and can promote cellular differen-
tiation and inhibit proliferation of cancer in vitro (Colston et al,
1981; Frampton et al, 1983; Brehier and Thomasset, 1988) as well
as inhibiting the invasive potential of human breast cancer cells in
vitro (Hansen et al, 1994) and inhibiting tumour-induced angio-
genesis (Majewski et al, 1993).
Furthermore, 1,25(OH)2D3 can induce apoptosis in human
breast cancer and leukaemic cell lines (James et al, 1995; Elstner
et al, 1996). The hormone mediates its action through its nuclear
receptor (vitamin D receptor, VDR) which is a transactivating
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hormone receptor superfamily of genes (Evans, 1988). In addition,
there is evidence to support the notion of another, non-genomic
pathway by which vitamin D can initiate various biological
responses (Norman et al, 1996; Nemere and Farach-Carson, 1998).
The calcaemic effect of 1,25(OH)2D3 in vivo limits its potential
as a therapeutic agent. The synthetic analogue seocalcitol is 50–200
times more potent than vitamin D in inhibiting growth and indu-
cing differentiation of cancer cell lines (Hansen et al, 1997;
Kissmeyer et al, 1997). In vivo studies in animal models have
shown that seocalcitol can cause regression of established tumours,
prevent the development of metastases, and prolong survival time
in tumour-bearing animals (Colston et al, 1992, 1997; James et
al, 1998; Lokeshwar et al, 1999; Nickerson and Huynh, 1999), with
signiﬁcant inhibition of tumour progression achieved at doses that
do not cause signiﬁcant hypercalcaemia (Colston et al, 1992).
Furthermore, seocalcitol inhibits growth of pancreatic cancer cells
in vitro (Zugmaier et al, 1996; Pettersson et al, 2000) and inhibits
growth in vivo of pancreatic cancer xenografts in immunodeﬁcient
mice (Colston et al, 1997). Seocalcitol was well tolerated in a phase
I clinical study in patients with breast or colorectal cancer, with
dose-dependent hypercalcaemica (Gulliford et al, 1998). Conse-
quently a phase II study was performed in patients with
inoperable pancreatic cancer to determine the objective anti-
tumour activity of seocalcitol in this disease.
MATERIALS AND METHODS
The study was a multi-centre, open, non-controlled trial at the
Beatson Oncology Centre, Glasgow; St George’s Hospital, London;
and the Royal Marsden Hospital, London and Surrey. The study
was approved by the Local Research Ethics Committee of all parti-
cipating institutions, and all patients gave written, informed
consent.
Eligible patients were those with histologically or cytologically
conﬁrmed inoperable carcinoma of the exocrine pancreas, age 518
years, WHO performance status of 0–2, a life expectancy of at least
3 months, an albumin-corrected serum calcium of 52.65 mmol l
71,
and adequate renal (gfr 540 ml min
71; serum creatinine 52 times
the upper limit of normal), hepatic (bilirubin 51.5 times the upper
limit of normal) and haematological (Hb 510 g dl
71, WBC
53.0610
9l 71, platelets 5100610
9l 71) function. Patients with
a history of hypercalcaemia, disordered calcium metabolism, anti-
cancer therapy within the previous 4 weeks, or calcium-lowering
therapy (including corticosteroids above the equivalent of 25 mg
prednisolone daily) within the previous 2 weeks, were excluded.
The study comprised two parts: (i) a dose-ﬁnding phase to
determine the individual maximum tolerated dose (MTD) for each
patient; and (ii) a treatment maintenance phase to determine the
response to seocalcitol and the tolerability of treatment.
Patient treatment schedules
Patients started seocalcitol at a dose of 20 mg given as a once-daily
dose just prior to the evening meal. The seocalcitol dose was
increased every 2 weeks until a dose was reached that resulted in
hypercalcaemia, this being deﬁned at the beginning of the study
as either a fasting albumin-corrected serum calcium of
42.80 mmol l
71 or non-fasting albumin-corrected serum calcium
of 43.0 mmol l
71. During most of the study, there was no special
limit for fasting serum calcium, and the dose was kept constant for
serum calcium values between 2.80 and 3.00 mmol l
71. When a
patient developed hypercalcaemia above 3.00 mmol l
71, seocalcitol
was stopped for 1 week and then recommenced at the dose level
immediately below the dose causing hypercalcaemia. Thereafter
no further dose adjustment was performed unless further episodes
of hypercalcaemia occurred. Dose levels of 5, 10, 15, 20, 30, 40 and
60 mg daily were allowed.
Calcium diet
Patients were seen by a dietician prior to starting seocalcitol ther-
apy and after 4 weeks of treatment, and dietary calcium intake
assessed. All patients were given written advice on dietary calcium
intake and encouraged to adhere to a ‘lowest acceptable calcium
diet’ (400 mg day
71 of calcium) excluding all dairy products.
Patients with inoperable pancreatic cancer are prone to cachexia
and poor nutrition. However, it was considered justiﬁed to advise
these patients to take a low-calcium diet given the in vivo data
supporting a higher anti-tumour activity with increased seocalcitol
dose (Colston et al, 1992). The involvement of dieticians in these
assessments was an attempt to achieve a low-calcium diet without
further compromising patients’ nutritional status. Dietary compli-
ance was checked at follow-up visits by individual investigators.
Assessment of toxicity and response
Prior to starting therapy, all patients underwent clinical assessment
and measurement of full blood count, serum urea, electrolytes,
liver function tests, glucose, parathyroid hormone and CEA. Serum
albumin, creatinine, total calcium and ionised calcium were also
measured and the serum calcium corrected for albumin using the
following formula: albumin corrected serum calcium=total serum
calcium+[(40-serum albumin)60.02]. Glomerular ﬁltration rate
(ml min
71) was calculated on an 8-h urine collection. Chest X-
ray and CT scan of the abdomen (and other sites of measurable
disease as appropriate) were performed up to 2 weeks prior to
starting therapy. The presence and severity of the following signs
and symptoms of pancreatic cancer were recorded: reﬂux, pain,
anorexia, nausea, vomiting, change in bowel habit and dyspnoea.
The serum albumin, calcium (total), creatinine and ionised
calcium were measured weekly until the serum albumin-corrected
calcium had been stable for 4 weeks at the maximum intended
seocalcitol dose. Thereafter samples were measured at 4-weekly
intervals. The full blood count and other biochemical analyses
(urea, electrolytes, glucose, parathyroid hormone) were measured
at 4-week intervals throughout the study.
Toxicity was graded based upon the SWOG CTC proﬁle (Green
and Weiss, 1992) and was recorded at 4-weekly intervals through-
out the study. Similarly, physical examination and assessment of
the signs and symptoms of pancreatic cancer were measured at
every 4 weeks throughout the study. Disease assessments by chest
X-ray, CT scan of the abdomen (and other sites as at pre-treat-
ment) were repeated after 12, 24 and 52 weeks during the study
and at other times as clinically indicated. Response assessments
were determined using the SWOG criteria (Green and Weiss,
1992). Patients continued seocalcitol for up to 52 weeks but were
withdrawn earlier if there was evidence of disease progression or
unacceptable toxicity. Treatment could be extended on a compas-
sionate use basis for patients having response or stable disease after
1 year.
Statistics
The number of patients for inclusion in the study was determined
according to Gehan’s 2-stage design for estimating the response
rate (Gehan, 1961). Thus the sample size calculation was based
on the requirement of stopping the study at an early stage if the
response rate is below 20%, and of estimating the response rate
with a standard error less than 0.10. Therefore if there was no
objective tumour response (complete or partial) among the ﬁrst
14 evaluable patients (patients completing at least 8 weeks of
seocalcitol), recruitment of patients would stop. Patients who did
not complete at least 8 weeks of seocalcitol were replaced. Addi-
tional patients would be included if there was one or more
responses in the ﬁrst 14 patients according to Gehan’s design.
Duration of stable disease was measured from the start of seocalci-
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to treatment failure was deﬁned as the time from start of treatment
until progression was ﬁrst detected or the patient went off study
due to clinical deterioration (without tumour measurements) or
the need for other anticancer treatments. Overall survival was
measured from the start of seocalcitol treatment until death from
any cause.
RESULTS
Patient characteristics
A total of 43 patients were enrolled from December 1995 with the
ﬁnal patient completing treatment in June 1999. The mean age was
60.7 years (range 38–77), 29 were male and 14 female, 38 of
Caucasian origin with three Negro and two of Oriental/Asian
origin. Forty-one patients had a histological or cytological diagno-
sis of carcinoma. One further patient had a diagnosis of pancreatic
cancer made on radiological evidence but without histological or
cytological conﬁrmation. A further patient was enrolled into the
study in the belief that he had histological or cytological conﬁrma-
tion of pancreatic cancer but no biopsy had been performed. CT-
guided biopsy of a pancreatic mass was subsequently performed
and did not conﬁrm that the lesion was malignant and the patient
was then withdrawn from the study (subsequently post-mortem
conﬁrmed the diagnosis of carcinoma of the exocrine pancreas).
Of the 41 patients with a conﬁrmed diagnosis of pancreatic cancer,
there was one case of a neuroendocrine cancer, one of carcinoma
of unknown type, and 39 of adenocarcinoma, with differentiation
classiﬁed as well (two patients), moderate (ﬁve patients), poor
(four patients) and unknown (28 patients). Previous non-surgical
anti-cancer treatment included palliative chemotherapy (12
patients), radiation therapy (two patients) with no patients having
received prior hormonal therapy. Distant metastases were observed
in 26 patients including liver (19 patients), lung (seven patients),
lymph nodes (three patients) and peritoneal (one patient) metas-
tases.
Patient population
All patients attended for screening and investigations. However, of
the intention-to-treat population, seven patients were withdrawn
prior to starting therapy due to clinical deterioration (four
patients), deteriorating liver function tests (one patient) and refusal
to comply with diet (two patients). Thus 36 patients started seocal-
citol therapy and formed the patient population that was evaluable
for toxicity. Fourteen patients completed at least 8 weeks treatment
and were evaluable for analyses of efﬁcacy. Twenty-two patients
were withdrawn before completing sufﬁcient therapy for evaluation
of efﬁcacy, due to clinical disease-related deterioration (14
patients), death due to disease progression (six patients), inability
to adhere to diet (one patient), and lack of conﬁrmation of diag-
nosis on histology/cytology (one patient). Of the 14 patients who
were evaluable for analyses of efﬁcacy, four patients had locally
advanced disease and 10 had distant metastases (liver (eight
patients), liver and lung (one patient), lung and lymph nodes
(one patient)).
Calcium levels and seocalcitol dose
The individual maximum tolerated dose was deﬁned as the highest
non-calcaemic dose used, i.e. the ﬁnal dose given at the end of the
titration phase unless the patient subsequently experienced hyper-
calcaemia at that dose. The individual MTD could be determined
in 29 of the 36 patients in the treated population. The remaining
seven patients experienced hypercalcaemia at the ﬁnal dose given
and had not received lower doses previously without developing
hypercalcaemia. One patient developed hypercalcaemia at the ﬁnal
dose given, and had previously received the dose step below with-
out developing hypercalcaemia, and this was therefore chosen as
the individual MTD.
The individual MTD for the patient population who received
seocalcitol ranged from 5 to 60 mg day
71. However the individual
MTD could not be reliably determined in seven patients who were
withdrawn from the study during the titration phase for reasons
not related to treatment. The individual MTD in the 29 patients
who continued in the maintenance phase ranged from 5–
60 mg day
71 and is shown in Figure 1. The individual MTD for
the 14 patients who completed at least 8 weeks of treatment and
who were evaluable for response, ranged from 5–40 mg day
71
(Figure 2). The most common maximum non-calcaemic daily dose
was 15 mg day
71.
Toxicity
The most frequent toxicity was dose-related hypercalcaemia. There
was a signiﬁcant increase in the ratio of the end of treatment albu-
min-adjusted serum calcium to the corresponding baseline value of
1.13 (range 0.88–1.36; P50.001, n=36), and similarly for the ratio
of serum ionised calcium (1.11; range 0.99–1:38; P=0.001, n=36)
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Figure 1 Individual MTD for patients entering the maintenance phase of the study (n=36).
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P50.001, n=36).
Other frequently recorded symptoms included nausea, vomiting,
abdominal pain and change of bowel habit, although these symp-
toms could also be attributed to the underlying malignancy.
Grade 3/4 toxicity as determined by the SWOG criteria occurred
in only two patients with grade 4 haematological toxicity (one
patient), and grade 4 metabolic toxicity (one patient). One patient
developed grade 4 lowering of the lymphocyte count after 4 weeks’
treatment but with a normal total WBC and normal total neutro-
phil count. This patient came off study shortly after this due to
further biliary obstruction. The second patient developed grade 4
hypercalcaemia after 8 weeks treatment, and this resolved on stop-
ping seocalcitol for 2 weeks, after which seocalcitol was re-started
at a lower dose level.
Efﬁcacy analyses
There were no partial or complete responses. Of the 14 patients
who received at least 8 weeks of therapy, stable disease was
achieved in ﬁve patients at the ﬁrst disease assessment, with docu-
mented disease progression in six patients, and clinical
deterioration in keeping with disease progression in the remaining
three patients. Three of the patients with stable disease at the ﬁrst
assessment had locally advanced disease, and two had distant
metastases. The duration of stable disease in these ﬁve patients
ranged from 82–532 days (median 168 days).
The time to treatment failure for all patients who received
seocalcitol (n=36) ranged from 22 to 847 days (mean 120 days).
The median survival (n=36) was approximately 100 days, with only
10% of patients surviving for more than 1 year (Figure 3).
There was no correlation between individual dose and either
time to treatment failure or overall survival.
DISCUSSION
The most frequent toxicity of seocalcitol in advanced pancreatic
cancer is dose-dependent hypercalcaemia. The acceptable daily dose
in protracted administration in this study was 10–15 mg daily
which is similar to the dose of 7 mgm
72 per day estimated to
be tolerable for most patients in the phase 1 study in breast and
colorectal cancer (Gulliford et al, 1998). The other commonly
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 680–685reported events were nausea, vomiting, abdominal pain and change
of bowel habit. However in many cases these events could also be
attributed to the underlying malignancy.
Of the 36 patients who started treatment with seocalcitol, only
14 completed 8 weeks of treatment for evaluation of efﬁcacy
analyses, with 20 patients deteriorating clinically and being with-
drawn from the study prior to completing 8 weeks of treatment.
There were no objective responses to seocalcitol in these 14
patients. Thus seocalcitol is ineffective as a cytotoxic agent in
advanced pancreatic cancer in terms of anti-tumour efﬁcacy as
determined by a reduction in tumour volume.
Cancer of the exocrine pancreas is characterised by a natural
history of rapid disease progression in patients with inoperable
disease with obstructive jaundice and duodenal obstruction
frequent complications. Seocalcitol can inhibit cellular prolifera-
tion, induce differentiation and induce apoptosis in cancer cell
lines in vitro. However it is likely that it has a cytostatic rather than
cytotoxic effect in vivo, and its optimal clinical effect is therefore
most likely to be achieved in minimal disease states such as in
adjuvant therapy or as maintenance therapy after chemotherapy
has induced disease stabilisation. Of the 14 patients who received
at least 8 weeks of seocalcitol treatment, stable disease was achieved
in ﬁve patients with duration of stable disease ranging from 82 to
532 days (median duration of disease stabilisation of 168 days)
which is similar to the duration of beneﬁt in patients who respond
or have disease stabilisation with chemotherapy in this disease.
However, in a non-randomised phase II study, it can not be deter-
mined if this is due to the anti-tumour activity of seocalcitol or the
natural history of the disease in this selected group of patients.
Furthermore, in a non-randomised phase II study, time to disease
progression is not a valid study endpoint in the absence of a
comparator group of patients.
In conclusion, seocalcitol is safe when administered on a daily
basis over several weeks in patients with advanced pancreatic
cancer. No objective responses were seen. However, given the toler-
able toxicity proﬁle of this agent, and the pre-clinical evidence to
suggest that it may have activity in this malignancy, further studies
are required to determine if it produces a demonstrable biological
effect (e.g. by functional imaging such as with PET scanning) in
the absence of objective responses which would justify proceeding
to subsequent randomised studies to explore the effect of seocalci-
tol on overall survival when given in combination with
chemotherapy, or as ‘maintenance therapy’ after chemotherapy in
advanced disease, or in the adjuvant setting.
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